Background: Philip Morris International's IQOS ("I Quit Ordinary Smoking") device has increasingly penetrated the global tobacco market. In Israel, among the first countries with IQOS in its market, the IQOS device is sold in specialty stores and online; the heat sticks - HEETS - are sold at traditional retailers. Advertising restrictions in many contexts including Israel have shifted industry marketing efforts to point-of-sale (POS). Given the nuances of IQOS and HEETS product distribution and the importance of POS marketing, we conducted a pilot study of IQOS POS marketing strategies.
Methods: Data collectors assessed product offerings, pricing, promotional strategies, and placement in a sample of 15 IQOS retailers (10 convenience stores, 3 grocery stores, 2 tobacco shops) in three Israeli cities (Beer-Sheva, Haifa, Jerusalem).
Results: All retailers sold cigarettes; many carried other forms of tobacco (e.g., cigar products). Average price for a HEETS package was 30.2 Shekels (SD = 2.7); average price for the least expensive cigarette pack was 27.4 (SD = 1.5). HEETS were on average 9.5% more expensive than cigarettes. Posted ads were uncommon; rather, product displays were prominent. HEETS packages were often placed in a separate display box, at higher and more noticeable positions, and closer to consumers. Additionally, 11 retailers placed cigarettes and 10 placed HEETS near youth-oriented merchandise; 9 retailers placed cigarettes and HEETS, respectively, within 1 m of the floor.
Conclusions: This study represents an initial step in assessing IQOS POS practices - critical in advancing the ability to facilitate related research and regulation of emerging tobacco products in Israel and more broadly.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330751 | PMC |
| http://dx.doi.org/10.1186/s13584-018-0277-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Perceptions and intentions regarding IQOS among current US adults who use cigarettes and/or electronic nicotine delivery systems.
Tob Control
December 2024
School of Public Health, Georgia State University, Atlanta, Georgia, USA.
Introduction: IQOS was sold in the US in 2019-2021 and will likely return in 2024. It is important to anticipate IQOS' market penetration; thus, this study examined US adults' prior awareness and perceptions, intentions to try and reactions to an IQOS reduced-risk exposure statement.
Methods: 61 adults from three US cities were recruited to represent four tobacco use subgroups: current cigarette and never electronic nicotine delivery systems (ENDS) use; current cigarette and discontinued ENDS use; current cigarette and ENDS use; and former cigarette use and switched to ENDS.
Qualitative examination of US and Israeli adults' perceptions of IQOS advertising messages: modified exposure and risk statements, US FDA endorsement, and health warnings.
Nicotine Tob Res
November 2024
Braun School of Public Health and Community Medicine, Faculty of Medicine, The Hebrew University of Jerusalem and Hadassah Medical Center, Jerusalem, Israel.
Article Synopsis
- IQOS is a heated tobacco product promoted as a safer alternative to traditional cigarettes and has received FDA approval for its reduced exposure claims.
- A study of 84 interviews revealed varied perceptions about IQOS's advertising claims, with many participants interpreting claims of reduced exposure and risk differently and questioning the credibility of the studies backing those claims.
- The findings suggest a need for regulators and researchers to closely monitor how harm reduction messages are conveyed to prevent misunderstandings among consumers.
Caregiver restrictions on child access to tobacco in the home and home Smoking/Vaping bans among Black/African American women caregivers who smoke and live in Resource-limited, rural areas.
Prev Med Rep
December 2024
Department of Health Behavior and Health Education, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, 4301 West Markham St., #820, Little Rock, AR 72205, USA.
Objective: This study examined relationships between home smoking/vaping bans and caregiver restrictions on child access to tobacco in the home among rural, Black/African American caregivers who smoke.
Methods: Data were from the baseline survey of a randomized trial conducted in 2020-2022 among caregivers who smoke cigarettes and/or little cigars/cigarillos (N = 188). Logistic regressions examined associations between independent variables (tobacco product-specific and comprehensive home smoking/vaping bans) and dependent variables (caregiver keeps tobacco in the home; among caregivers with tobacco at home, caregiver restricts child tobacco access at home) Models were adjusted for caregiver tobacco use, income, and additional covariates based on stepwise selection.
Discussion of Heated Tobacco Products on Twitter Following IQOS's Modified-Risk Tobacco Product Authorization and US Import Ban: Content Analysis.
J Med Internet Res
October 2024
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Background: Understanding public opinions about emerging tobacco products is important to inform future interventions and regulatory decisions. Heated tobacco products (HTPs) are an emerging tobacco product category promoted by the tobacco industry as a "better alternative" to combustible cigarettes. Philip Morris International's IQOS is leading the global HTP market and recently has been subject to important policy events, including the US Food and Drug Administration's (FDA) modified-risk tobacco product (MRTP) authorization (July 2020) and the US import ban (November 2021).
View Article and Find Full Text PDFCan switching from cigarettes to heated tobacco products reduce consequences of pulmonary infection?
Respir Res
October 2024
Department of Immunology, Roswell Park Comprehensive Cancer Center, 665 Elm Street, Buffalo, NY, 14263, USA.
Rationale: While tobacco industry data suggests that switching from combustible cigarettes to heated tobacco products (HTPs), like IQOS, may reduce the users' exposure to respiratory toxicants, it is not known if using HTPs impacts the outcomes of acute respiratory infections.
Objectives: Does switching from cigarettes to HTPs improve responses to pulmonary infection.
Methods: We conducted experiments in which 3 groups of mice were pre-exposed to cigarette smoke for 8 weeks, followed by 8-week exposure to (1) HTPs (tobacco product switching), (2) air (smoking cessation), or (3) continued exposure to cigarette smoke.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!